CONGRESS ABSTRACT

Background: Amyloidosis is characterised by the extracellular accumulation of misfolded proteins forming amorphous aggregates called amyloid. Cardiac amyloidosis results from myocardial involvement in systemic amyloidosis, leading to impaired heart function. Besides myocardial involvement, cardiac amyloidosis may also directly and indirectly affect the central nervous system. Methods: This narrative review…

Wild-Type Transthyretin Amyloidosis (ATTRwt) is a progressive infiltrative cardiomyopathy, often preceded by typical extracardiac manifestations that can serve as early diagnostic red flags. While the cardiac phenotype is carachterised by concentric hypertrophy and is thus restrictive, management is frequently complicated by hemodynamic fragility that limits the use of standard…

Background: Cardiac amyloidosis in individuals of African ancestry is most commonly associated with the autosomal dominant transthyretin (TTR) gene variant Val142Ile, which is linked to an age-dependent increase in heart failure risk. This has relevant implications for early screening. Purpose: A 26-year-old African male on chronic hemodialysis since 2020…

An 84-year-old man with wild-type transthyretin cardiac amyloidosis (ATTRwt), permanent atrial fibrillation and moderately reduced ejection fraction (baseline LVEF 40%) was admitted with progressive dyspnea, fatigue and poor oral intake. On arrival he showed atrial fibrillation with rapid ventricular response (150 bpm), pulmonary congestion and signs of right-sided overload….

Introduction : Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive and systemic disease, caused by accumulation of misfolded transthyretin (TTR) proteins. This can involve extracardiac organs, leading to gastrointestinal (GI) and neuropathic symptoms that negatively impact quality of life. In the phase 3 HELIOS-B study of ATTR-CM patients, vutrisiran,…

An 88-year-old man with hypertension, dyslipidemia, mild glucose intolerance, and chronic kidney disease (eGFR ~40 ml/min) was reassessed for known wild-type transthyretin cardiac amyloidosis (ATTRwt) , diagnosed in 2022 after an initial episode of heart failure. The patient remained clinically stable and currently reports no exertional dyspnea, consistent with…

Background Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognised cause of heart failure in older adults, but real-world data in patients aged ≥80 years are limited. Methods A retrospective analysis was conducted on a real-world cohort of patients aged ≥80 years with cardiac amyloidosis, as part of routine clinical…

Cardiac TTR amyloidosis is an increasingly common diagnosis in the geriatric population. Although age is often a confounding factor, timely diagnosis remains crucial, especially in hereditary forms, due to its implications for family screening. This is why it is important to avoid diagnostic delays in patients who are often…